MaxCyte, Inc. (MXCT) Return on equity 2019–2025
MaxCyte, Inc. (MXCT) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-26.0%FY2025 · since FY2019: -94.8% → -26.0%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -26.0% | -6.1 pp |
| FY2024 | -19.9% | -3.6 pp |
| FY2023 | -16.3% | -7.1 pp |
| FY2022 | -9.3% | -2.0 pp |
| FY2021 | -7.3% | +28.3 pp |
| FY2020 | -35.6% | +59.2 pp |
| FY2019 | -94.8% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More MXCT financial trends
MXCT RevenueMXCT Net incomeMXCT Net marginMXCT Gross profitMXCT Gross marginMXCT Operating incomeMXCT Operating marginMXCT Operating cash flowMXCT Free cash flowMXCT Capital expendituresMXCT Stock buybacksMXCT Dividends paidMXCT Total assetsMXCT Total liabilitiesMXCT Shareholders’ equityMXCT overview →